clock December 24,2023
Sunshine Holdings sustains growth momentum in 1QFY25

Sunshine Holdings sustains growth momentum in 1QFY25

•   Consolidated revenue of Rs.14.2 billion, up by 6.5%

•   Healthcare revenue up 19.8% YoY to Rs.7.6 billion

•   Consumer records revenue of Rs.4.6 billion, down 1.9% YoY

 

Diversified  conglomerate Sunshine Holdings PLC (CSE: SUN) continued demonstrating resilience amidst prevailing macroeconomic conditions, reporting a topline growth of 6.5% YoY. The Group recorded a consolidated revenue of Rs.14.2 billion during the first quarter of the current financial year (1QFY25), with Profit after tax (PAT) contracting by 3.6% YoY to Rs.1.4 billion. The revenue increase was due to robust revenue growth in Healthcare, despite contraction in both Consumer and Agri sectors.

 

The Group’s Healthcare sector emerged as the largest contributor to Sunshine’s topline, accounting for 53.1% of total revenue, followed by Consumer at 32.4% and Agribusiness at 14.5%.

                                                                                           

Group CEO Shyam Sathasivam said, “As we navigate through the first quarter of FY25, Sunshine Holdings remains steadfast in its commitment to resilience and innovation.   We are acutely aware of the ongoing economic challenges, particularly the impact of adjusted direct and indirect taxes on consumer disposable income and have closely monitored these dynamics and implemented  measures to adapt and thrive. The Group’s ability to post robust results amidst these conditions is a testament to our  team’s hard work and relentless pursuit of excellence. Moving forward, we will continue to be agile and proactive, ensuring that we overcome the challenges ahead and seize new growth opportunities.”

 

Healthcare

 

During the period in review, the Group’s healthcare sector posted revenue of Rs.7.6 billion during the first quarter, a significant increase of 19.8% YoY backed by the increased topline of manufacturing and pharma businesses. Lina Manufacturing, the Group’s pharmaceutical manufacturing business, recorded revenue growth of 104.4% YoY, driven by higher volumes in the Metering Dose Inhaler (MDI) plant. Lina Manufacturing is now capable of supplying majority of the MDI requirement of the government.

 

Consumer

 

The consumer sector, encompassing both export and domestic businesses, reported a marginal decrease of 1.9% YoY in revenue to close at Rs. 4.6 billion. However, the sector showed an improvement of 2.6% YoY compared to 4QFY24 post the changes to the VAT structure in Jan 2024. Revenue from the Branded Tea and Confectionery businesses declined by 16.9% YoY, primarily due to a drop in sales volume. The export business recorded a 31.1% increase in revenue due to heightened demand from key clients and reduced tea costs.

Agribusiness

 

The Agribusiness sector of the Group, represented by Watawala Plantations PLC (CSE: WATA), reported a revenue of Rs. 2.1 billion, reflecting a 12.1% YoY contraction.  This stemmed from a 13.8% YoY contraction in the palm oil business. The dairy business recorded a revenue of Rs. 326 million. The recovery of milk production volumes and reduced feed cost resulted in the dairy business recording a PAT margin of 8.2% in 1QFY25, compared to negative 12.8% in the same period last year.

 

About Sunshine Holdings PLC

Sunshine Holdings PLC is a publicly listed conglomerate contributing to ‘nation-building’ by creating value in vital sectors of the Sri Lankan economy – in the healthcare and consumer sectors, with strategic investments in agribusiness.

Established in 1967, the Group is now home to leading Sri Lankan brands such as Zesta Tea, Watawala Tea, Ran Kahata, Daintee, Milady, Healthguard Pharmacy and Lina Manufacturing, with over 2,000 employees and revenue over LKR 55 billion. The business units comprise of Sunshine Healthcare Lanka, Sunshine Consumer Lanka, and Watawala Plantations PLC, which are leaders in their respective sectors and most of them certified as a “Great Place to Work” in 2023.

We believe that the purpose of our existence is to “Bring good things to life” and that means, we will make available to all Sri Lankans, quality medicines and consumer products at affordable prices therefore ensuring a better quality of life for all. Our growth has been defined by our commitment to conduct our business ethically and staying true to our values.

 

 

You Must be Registered Or Logged in To Comment Log In?

Related News

Please Accept Cookies for Better Performance